Display options
Share it on

Nat Commun. 2016 Sep 22;7:12777. doi: 10.1038/ncomms12777.

Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities.

Nature communications

Abdelhakim Ahmed-Belkacem, Lionel Colliandre, Nazim Ahnou, Quentin Nevers, Muriel Gelin, Yannick Bessin, Rozenn Brillet, Olivier Cala, Dominique Douguet, William Bourguet, Isabelle Krimm, Jean-Michel Pawlotsky, Jean-François Guichou

Affiliations

  1. INSERM U955 'Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers', Hôpital Henri Mondor, Université Paris-Est, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.
  2. CNRS UMR5048, Centre de Biochimie Structurale, Université de Montpellier, 29 rue de Navacelles, 34090 Montpellier, France.
  3. INSERM U1054, Centre de Biochimie Structurale, Université de Montpellier, 29 rue de Navacelles, 34090 Montpellier, France.
  4. Institut des Sciences Analytiques, CNRS UMR5280, Université Lyon 1, École Nationale Supérieure de Lyon, 5 rue de la Doua, 69100 Villeurbanne, France.
  5. National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.

PMID: 27652979 PMCID: PMC5036131 DOI: 10.1038/ncomms12777

Abstract

Cyclophilins are peptidyl-prolyl cis/trans isomerases (PPIase) that catalyse the interconversion of the peptide bond at proline residues. Several cyclophilins play a pivotal role in the life cycle of a number of viruses. The existing cyclophilin inhibitors, all derived from cyclosporine A or sanglifehrin A, have disadvantages, including their size, potential for side effects unrelated to cyclophilin inhibition and drug-drug interactions, unclear antiviral spectrum and manufacturing issues. Here we use a fragment-based drug discovery approach using nucleic magnetic resonance, X-ray crystallography and structure-based compound optimization to generate a new family of non-peptidic, small-molecule cyclophilin inhibitors with potent in vitro PPIase inhibitory activity and antiviral activity against hepatitis C virus, human immunodeficiency virus and coronaviruses. This family of compounds has the potential for broad-spectrum, high-barrier-to-resistance treatment of viral infections.

Conflict of interest statement

Inserm Transfert is the owner of patent EP 09306294.1 covering the family of cyclophilin inhibitors described, for which A.A.-B., L.C., J.-M.P. and J.-F.G. are inventors. All other authors declare no

References

  1. Biochim Biophys Acta. 2015 Oct;1850(10 ):2103-10 - PubMed
  2. Methods Mol Biol. 2010;596:433-46 - PubMed
  3. Nat Rev Drug Discov. 2013 Jan;12(1):5-7 - PubMed
  4. Nat Rev Drug Discov. 2013 Aug;12(8):644-5 - PubMed
  5. Hepatology. 2009 May;49(5):1460-8 - PubMed
  6. Circ J. 2013;77(5):1111-22 - PubMed
  7. J Med Chem. 2005 Apr 7;48(7):2457-68 - PubMed
  8. Hepatology. 2015 Oct;62(4):1013-23 - PubMed
  9. J Med Chem. 2015 Dec 24;58(24):9546-61 - PubMed
  10. Nat Chem Biol. 2009 Jun;5(6):407-13 - PubMed
  11. Nat Struct Biol. 2003 Jun;10(6):475-81 - PubMed
  12. Biochem Pharmacol. 2013 Mar 15;85(6):727-44 - PubMed
  13. Transplant Proc. 2006 Sep;38(7):2180-2 - PubMed
  14. Virus Res. 2014 May 12;184:44-53 - PubMed
  15. Antimicrob Agents Chemother. 2009 Mar;53(3):967-76 - PubMed
  16. PLoS Pathog. 2011 Oct;7(10):e1002331 - PubMed
  17. PLoS Pathog. 2014 Oct 02;10(10):e1004422 - PubMed
  18. Front Microbiol. 2015 May 22;6:517 - PubMed
  19. Mol Cell Biochem. 2012 Aug;367(1-2):227-36 - PubMed
  20. J Virol. 2001 May;75(10):4614-24 - PubMed
  21. Acta Crystallogr D Biol Crystallogr. 2005 May;61(Pt 5):513-9 - PubMed
  22. Bioorg Med Chem. 2009 Apr 15;17(8):3177-88 - PubMed
  23. Gastroenterology. 2014 May;146(5):1361-72.e1-9 - PubMed
  24. Mini Rev Med Chem. 2009 Jul;9(8):956-61 - PubMed
  25. PLoS Biol. 2010 Jul 27;8(7):e1000439 - PubMed
  26. Genome Biol. 2005;6(7):226 - PubMed
  27. Proteins. 1999 Nov 1;37(2):228-41 - PubMed
  28. Biochemistry. 2009 Jul 7;48(26):6268-77 - PubMed
  29. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3686-90 - PubMed
  30. Front Physiol. 2013 Apr 11;4:76 - PubMed
  31. Chembiochem. 2011 Mar 21;12(5):802-10 - PubMed
  32. EMBO Rep. 2000 Nov;1(5):428-34 - PubMed
  33. J Med Chem. 2014 Sep 11;57(17):7145-59 - PubMed
  34. Pharmacogenetics. 1995 Aug;5(4):255-8 - PubMed
  35. Nature. 2005 Mar 31;434(7033):658-62 - PubMed
  36. Nat Rev Drug Discov. 2007 Mar;6(3):211-9 - PubMed
  37. J Hepatol. 2016 Jun;64(6):1305-14 - PubMed
  38. Cell Death Dis. 2013 Oct 31;4:e888 - PubMed
  39. Top Curr Chem. 2012;317:1-32 - PubMed
  40. J Immunol. 2008 Aug 15;181(4):2831-45 - PubMed
  41. J Med Chem. 2006 Feb 9;49(3):900-10 - PubMed
  42. J Med Chem. 2009 Sep 10;52(17):5295-8 - PubMed
  43. Cell Calcium. 2011 Sep;50(3):222-33 - PubMed
  44. Nat Chem. 2009 Jun;1(3):187-92 - PubMed
  45. N Engl J Med. 1978 May 25;298(21):1157-9 - PubMed

Publication Types